Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
Key Details
- 1Median Technologies received FDA clearance for Eyonis LCS, an AI/ML-powered computer-aided detection software as a medical device.
- 2Designed to assist in the interpretation of low-dose CT (LDCT) scans for lung cancer screening, addressing inter-reader variability.
- 3Eyonis LCS is reported as the first end-to-end FDA-cleared device specifically for lung cancer screening workflows.
- 4Performance testing showed 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV).
- 5The tool is aimed at improving screening access and diagnostic accuracy, as well as reducing unnecessary procedures.
Why It Matters
FDA clearance for Eyonis LCS marks a significant advancement in AI-assisted lung cancer screening by leveraging CT imaging. The device's strong performance metrics and focus on workflow efficiency could help radiology practices meet increasing screening demands while improving patient outcomes.
Source
Radiology Business
Related News
•Radiology Business
AI-Powered Tool Streamlines CT Scan Prioritization in Emergency Departments
An AI-based CT queue system significantly reduces wait times for ED patients by prioritizing scans likely to reveal critical findings.
•Radiology Business
AI Workflow Enables General Radiologists to Match Breast Specialists in Screening
AI-powered workflow helps generalist radiologists detect breast cancer at rates comparable to specialists.
•AuntMinnie
Radiologists Struggle to Spot AI-Generated Radiology Images
Radiologists correctly identify AI-generated images 75% of the time, with CT and MRI images being particularly challenging to spot.